Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

Osteoporos Int. 2017 Oct;28(10):3067-3068. doi: 10.1007/s00198-017-4108-y. Epub 2017 Jun 6.

Authors

T Lehmann¹, D Aeberli²

Affiliations

¹ Rheumatological Practice OsteoRheuma Bern, 3011, Bern, Switzerland.
² Department of Rheumatology, Immunology and Allergology, University Hospital and University of Bern, CH-3012, Bern, Switzerland. daniel.aeberli@insel.ch.

PMID: 28589418
DOI: 10.1007/s00198-017-4108-y

No abstract available

Publication types

Letter

MeSH terms

Aged
Bone Density Conservation Agents / therapeutic use*
Denosumab / therapeutic use*
Drug Substitution
Female
Humans
Middle Aged
Osteoporosis, Postmenopausal / drug therapy
Osteoporotic Fractures / prevention & control*
Spinal Fractures / prevention & control*
Zoledronic Acid / therapeutic use*

Substances

Bone Density Conservation Agents
Denosumab
Zoledronic Acid